Company Overview and News

 
Leong Hup’s much-awaited return to the stock market

10h thestar.com.my
IT was in February last year when Tan Sri Francis Lau Tuang Nguang – dubbed the “chicken king” – first revealed to StarBiz his plan to relist the company his family co-founded – Leong Hup International Bhd – by 2019 or 2020.
9385 7252 BSMAF 1818

 
Teo Seng Capital narrows 2Q net loss, declares 0.5 sen dividend

2018-08-20 theedgemarkets
KUALA LUMPUR (Aug 20): Teo Seng Capital Bhd narrowed its net loss to RM528,000 in the second quarter ended June 30, 2018 (2QFY18) from RM7.3 million a year ago, on higher contribution from both its poultry farming, and investment and trading segments.
7252 BSMAF 1818

 
Two resign from Teo Seng Capital’s board to comply with CG requirements

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): Teo Seng Capital Bhd today announced the resignation of two of its board members Tan Sri Lau Tuang Nguang and Na Yok Chee, to downsize the number of board members, in order to comply with the Malaysian Code on Corporate Governance 2017.
7252 BSMAF 1818

4
Nam Hiok Joo is now Teo Seng Capital's new MD

2018-06-27 theedgemarkets
KUALA LUMPUR (June 27): Poultry farming group Teo Seng Capital Bhd announced that Nam Hiok Joo has taken over the role of the group's new managing director (MD), effective today, following the retirement of his 62-year-old brother Nam Yok San from the post on the same day.
7252 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...